INVVY - INVVY STOCK NEWS

Indivior PLC (LON: INDV) released its financial results for Q1 2022, ending March 31, 2022. Although the specific figures were not disclosed in the PR, the company emphasizes its commitment to developing medicines for substance use disorders and serious mental illnesses. Indivior's global portfolio targets opioid use disorder and aims to address associated chronic conditions. The company continues to operate globally, employing over 900 individuals, and is focused on expanding its product pipeline for better patient access.

Indivior announces its commitment to enhance access to medications addressing opioid use disorder, amid a nationwide spike in fentanyl-related overdoses. The CDC reports over 105,000 overdose deaths in the year ending October 2021, with a significant proportion linked to synthetic opioids. Indivior's CEO emphasizes the urgent need for evidence-based treatment solutions, particularly in underserved communities facing barriers to care. The company aims to address racial and ethnic disparities in treatment and emphasizes the importance of access for individuals involved in the criminal justice system.

Indivior PLC has published modeling data in JCI Insight exploring how buprenorphine can mitigate fentanyl-induced respiratory depression. The study indicates that buprenorphine plasma concentrations of 2 ng/mL and above may protect chronic opioid users from respiratory depression triggered by fentanyl. Although the study was conducted in a controlled environment with a limited number of participants, it suggests that buprenorphine's ability to occupy mu-opioid receptors can prevent respiratory issues when combined with fentanyl. Further research in real-world settings is warranted.

Indivior PLC announced on March 31, 2022, the initiation of formal consultations with shareholders regarding a potential additional listing on a major US stock exchange. The Board believes that this move could enhance the company’s profile in its largest market, where approximately 80% of its net revenue is generated. Indivior aims to attract a broader base of biopharma investors and research analysts, with a potential resolution planned for September 2022. The earliest implementation could occur in Spring 2023.

Indivior PLC (LON: INDV) reported its financial results for the fiscal year ending December 31, 2021, showcasing its commitment to addressing substance use disorders and mental illnesses. The company aims to enhance access to evidence-based treatments globally. Indivior's product pipeline focuses on opioid use disorder treatments and related chronic conditions. The earnings release, investor presentation, and additional materials are available online, with a webcast presentation scheduled for today at 8:00 AM US EST.

Indivior announced the publication of a clinical pharmacology study in PLOS ONE, demonstrating that buprenorphine can significantly reduce respiratory depression caused by fentanyl in both healthy volunteers and opioid-tolerant patients. Results showed that the decrease in minute ventilation was reduced by nearly 60% with buprenorphine compared to a placebo. The FDA recently updated the label for SUBLOCADE to include data from this study, affirming its efficacy in treating opioid use disorder amidst the ongoing opioid crisis, which saw over 101,000 overdose deaths in the U.S. within a year.

Indivior PLC (LON: INDV) presented a study at the NCCHC 2021 conference focusing on opioid use disorder (OUD) treatment barriers in the criminal justice system. The mixed methods study included literature reviews and interviews with addiction specialists. Key findings revealed that nearly 20% of state prison inmates regularly use opioids, highlighting stigma and resource shortages that restrict treatment access. The study emphasized a preference for the injectable version of buprenorphine, while patient concerns about withdrawal were notable. Data showed similar emergency department visit rates for criminal justice-involved and non-involved individuals receiving treatment.

Indivior PLC announced new findings at the CSAM-SMCA 2021 Scientific Conference held virtually from October 21-23, 2021. The data presented focuses on addressing challenges in treating opioid use disorder (OUD). Chief Scientific Officer Christian Heidbreder emphasized the importance of science-based treatment options. Key abstracts include studies on heroin users' management during COVID-19 and the benefits of buprenorphine injections. Indivior is dedicated to transforming addiction treatment and enhancing patient care worldwide.

Indivior PLC presented new research at the CPDD 83rd Annual Scientific Virtual Meeting, highlighting critical issues in opioid use disorder during the COVID-19 pandemic. The data covers topics like the impact of COVID-19 on recovery rates, comparative studies of SUBLOCADE maintenance doses, and patient outcomes in diverse healthcare settings. Key findings include a 26% increase in recovery difficulty due to COVID-19 and a higher retention rate among patients using 300 mg SUBLOCADE doses. Furthermore, the study revealed an alarming rise in buprenorphine-involved mortality rates from 0.006 in 2010 to 0.068 in 2017, emphasizing the ongoing opioid crisis.